

## AUTHOR'S CORRECTION

# Carbapenem Susceptibility Testing Errors Using Three Automated Systems, Disk Diffusion, Etest, and Broth Microdilution and Carbapenem Resistance Genes in Isolates of *Acinetobacter baumannii-calcoaceticus* Complex

Ana Elizabeth Markelz, Katrin Mende, Clinton K. Murray, Xin Yu, Wendy C. Zera, Duane R. Hospenthal, Miriam L. Beckius, Tatjana Calvano, and Kevin S. Akers

Brooke Army Medical Center, Fort Sam Houston, Texas, and Uniformed Services University of the Health Sciences and Infectious Disease Clinical Research Program, Bethesda, Maryland

Volume 55, no. 10, p. 4707–4711, 2011. Page 4708, Table 1: The EUCAST breakpoints for % VME, % ME, and % mE and footnote e should appear as shown below.

**TABLE 1** MICs and error rates obtained for 107 single-patient clinical isolates of the *Acinetobacter baumannii-calcoaceticus* complex tested for susceptibility to imipenem, meropenem, and doripenem by manual and automated methods compared to BMD by using CLSI, FDA, and EUCAST criteria

Drug and method <sup>a</sup>	MIC ( $\mu\text{g/ml}$ )		Result <sup>b</sup> using the following criteria:											
	50%	90%	CLSI <sup>c</sup>				FDA <sup>d</sup>				EUCAST <sup>e</sup>			
			% S	% VME	% ME	% mE	% S	% VME	% ME	% mE	% S	% VME	% ME	% mE
<b>Imipenem</b>														
DD			39.6	0.0	0.9	1.9	39.6	0.0	0.9	1.9	31.8	0.0	0.0	19.6
ET	$\geq 32$	$\geq 32$	39.3	0.0	0.9	3.7	39.3	0.0	0.9	3.7	13.1	0.0	0.0	12.1
MicroScan	$\geq 8$	$\geq 8$	43.0	3.7	1.9	2.8	43.0	3.7	1.9	2.8	38.3	0.9	0.9	53.3
Phoenix	$\geq 8$	$\geq 8$	41.1	1.9	0.9	2.8	41.1	1.9	0.9	2.8	37.4	0.9	0.0	23.4
Vitek 2	$\geq 16$	$\geq 16$	39.3	0.9	0.0	4.7	39.3	0.9	0.0	4.7	38.3	0.0	0.0	27.1
BMD	$\geq 16$	$\geq 16$	37.4				37.4				15.0			
<b>Meropenem</b>														
DD			38.3	0.0	0.0	3.7	38.3	0.0	0.0	3.7	8.4	0.0	0.0	14.0
ET	$\geq 32$	$\geq 32$	36.4	0.0	0.0	3.7	36.4	0.0	0.0	3.7	19.6	0.0	0.0	12.0
MicroScan	$\geq 8$	$\geq 8$	38.3	0.0	0.9	3.7	38.3	0.0	0.9	3.7	37.4	0.0	0.9	21.3
Phoenix	$\geq 8$	$\geq 8$	39.2	1.9	0.9	4.7	39.2	1.9	0.9	4.7	35.5	1.9	0.9	15.9
Vitek 2	$\geq 16$	$\geq 16$	39.3	0.0	0.9	4.7	39.3	0.0	0.9	4.7	36.4	0.0	0.0	18.7
BMD	$\geq 16$	$\geq 16$	35.5				35.5				19.6			
<b>Doripenem</b>														
DD			NA	NA	NA	NA	35.5	30.8	0.9	NA	7.5	0.0	0.0	11.2
ET	$\geq 32$	$\geq 32$	NA	NA	NA	NA	6.5	2.8	0.0	NA	6.5	0.0	0.0	8.4
Vitek 2	$\geq 8$	$\geq 8$	NA	NA	NA	NA	21.5	17.8	0.0	NA	21.5	1.9	0.0	20.6
BMD	$\geq 16$	$\geq 16$	NA				3.7				3.7			

<sup>a</sup> DD, disk diffusion; ET, Etest; Vitek 2, Vitek 2 cards (AST-GN24 card and AST-XN04 extension card).

<sup>b</sup> S, susceptible; VME, very major errors; ME, major errors; mE, minor errors; NA, not applicable (intermediate breakpoints for doripenem were not defined).

<sup>c</sup> CLSI breakpoints for imipenem/meropenem were as follows: for susceptibility,  $\leq 4 \mu\text{g/ml}$  ( $\geq 16 \text{ mm}$ ); for intermediacy,  $8 \mu\text{g/ml}$  (14 to 15 mm); for resistance,  $\geq 16 \mu\text{g/ml}$  ( $\leq 13 \text{ mm}$ ) (3).

<sup>d</sup> FDA breakpoints were as follows: for imipenem/meropenem,  $\leq 4 \mu\text{g/ml}$  ( $\geq 16 \text{ mm}$ ) for susceptibility,  $8 \mu\text{g/ml}$  (14 to 15 mm) for intermediacy, and  $\geq 16 \mu\text{g/ml}$  ( $\leq 13 \text{ mm}$ ) for resistance; for susceptibility to doripenem,  $\leq 1 \mu\text{g/ml}$  ( $\geq 17 \text{ mm}$ ).

<sup>e</sup> EUCAST breakpoints were as follows: for imipenem,  $\leq 2 \mu\text{g/ml}$  ( $\geq 23 \text{ mm}$ ) for susceptibility and  $> 8 \mu\text{g/ml}$  ( $< 17 \text{ mm}$ ) for resistance; for meropenem,  $\leq 2 \mu\text{g/ml}$  ( $\geq 21 \text{ mm}$ ) for susceptibility and  $> 8 \mu\text{g/ml}$  ( $< 15 \text{ mm}$ ) for resistance; for doripenem,  $\leq 1 \mu\text{g/ml}$  ( $\geq 21 \text{ mm}$ ) for susceptibility and  $> 4 \mu\text{g/ml}$  ( $< 15 \text{ mm}$ ) for resistance (6). Values between susceptible and resistant are considered intermediate.